The bear market for biotech stocks has recently shown signs of slackening, but there are biotech stocks whose shares are already up by 50% or more to start this year.
These three have attracted investors’ interest because they all have new therapies with wide applications that have shown great promise.
This post originally appeared at The Motley Fool.